DRAPER, Utah, Nov. 20, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that Dr. Tracy K. Gibbs is scheduled to begin an extended strategic business and marketing tour of Asia.
"This 17-day multi-country tour of Malaysia, Philippines, and Japan will include several important business development meetings with our valued existing clients like Flantech Asia and UNO International," stated Dr. Tracy K. Gibbs, Nutranomics CEO. "In addition to meetings with long-term clients, we also plan to meet with many more potential new clients that have expressed an interest in working with us to develop new business opportunities."
Dr. Gibbs is currently scheduled to be in Malaysia (November 27th - 30th), Philippines (December 1st - 8th), and Japan (December 9th - 13th).
"As we continue to focus on building the Nutranomics brand around the world, this particular tour has been designed to help accelerate our Asian growth strategy and to help us expand our footprint in these important health food supplement markets," concluded Dr. Gibbs.
About Nutranomics
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at ir@nutranomics.com or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, but are not limited to, planned Asian growth strategies, the acquisition of new clients/customers, and future potential sales. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov . These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
